Question 1

What is tesamorelin?

Accepted Answer

Tesamorelin is a laboratory-made version of a hormone a person already produces, acting one step upstream of growth hormone itself. A 2011 review in Drugs puts the chemistry plainly. Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone that stimulates the synthesis and release of endogenous growth hormone. Endogenous there means the hormone the body makes for itself. That one sentence carries the whole design. Tesamorelin supplies no growth hormone from outside; it asks the pituitary gland to release more of what is there, so its action needs a pituitary that still works. The same family holds sermorelin and CJC-1295, which a 2021 anti-doping paper groups with it as the larger GHRH synthetic analogs. Family resemblance is not shared evidence, and those records sit separately at the HGH overview, the Sermorelin overview and the CJC-1295 overview.

Question 2

What is tesamorelin approved for?

Accepted Answer

One indication, named with unusual precision, in one group of patients. A 2011 note in Nature Reviews Drug Discovery records the decision itself. Tesamorelin was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, in November 2010. The label narrows that much further, and a 2016 reimbursement review quotes the criteria. They are a waist of 95 cm or more for males and 94 cm or more for females, confirmed by a VAT level > 130 cm2 by computed tomography (CT) scan, in treatment-experienced adult HIV-infected patients with lipodystrophy. The same review records the schedule the regulator approved, which is 2 mg (two 1 mg vials) injected subcutaneously once a day. Read the qualifiers rather than the headline. A waist number, a scan number, an HIV diagnosis and earlier therapy are all part of what was approved.

Question 3

What does that approval not cover?

Accepted Answer

It covers fat accumulation in people with HIV. It does not reach weight loss, physique, ageing or athletic performance, and the reviews say so in their own words. A 2012 review written two years after the approval put the position in one line: limited data support off-label uses of tesamorelin at this time. The trials published since have mostly stayed inside that same population. A 2026 primer for sports medicine physicians is blunter, recording that tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence. It adds that across the peptides it covered, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. An approval is a statement about one dossier, in one population, held to one standard of proof rather than a general verdict. It says nothing about an unlabelled vial holding the same molecule.

Question 4

How far into people has tesamorelin been studied?

Accepted Answer

Further than almost any compound covered on this site, and almost entirely inside a single diagnosis. Two 2026 reviews count the randomised record. One reports that five RCTs evaluating Tesamorelin were included in the analysis, and the other pooled four RCTs (909 patients). The largest single trial randomly assigned 412 patients with HIV who had an accumulation of abdominal fat to tesamorelin or placebo for 26 weeks. A second ran a 12-month study of 404 HIV-infected patients with excess abdominal fat in the context of antiretroviral therapy. In both of them, patients and investigators were blinded to treatment assignment throughout the study. So the human record is large, randomised and properly blinded, which is rare for anything covered on this site. Every participant in it had HIV, and that single fact governs how far the rest of it carries.

Question 5

Does tesamorelin work in the condition it was approved for?

Accepted Answer

In the patients these trials enrolled it did, and the numbers line up well from one trial to the next. In the 2007 trial the measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group. Blood fats moved with it, and in the same patients the levels of triglycerides decreased by 50 mg per deciliter and increased by 9 mg per deciliter, respectively. The 2010 trial landed in the same place, reporting that tesamorelin reduces visceral fat by approximately 18% in HIV-infected patients with central fat accumulation. A 2026 meta-analysis pooled that evidence and found Tesamorelin was associated with significant reduction in visceral adipose tissue. Notice what was measured, and in whom. These are scan readings of deep belly fat in people whose fat had moved during HIV therapy, rather than scale weight in a healthy adult.

Question 6

Will tesamorelin get rid of belly fat?

Accepted Answer

This is the most-asked question about tesamorelin, and the trials answered a narrower version of it. What they measured was visceral adipose tissue, the deep fat packed around the organs, in patients whose fat had moved during HIV therapy. A 2011 review then adds the half that most summaries leave out: subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in those trials. Subcutaneous fat is the layer a person can pinch, and it is what most people mean by belly fat. So the answer has two halves that pull against each other. Deep abdominal fat fell measurably on a scan, and the pinchable layer did not move. Those are different questions, and the second has not been asked outside HIV among the research behind this page.

Question 7

Will you lose weight taking tesamorelin?

Accepted Answer

Scale weight was not the endpoint in any of these trials, and the distinction matters more here than it usually does. A 2026 meta-analysis reports that Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy. Body composition means the split between fat tissue and lean tissue, and lean mass rising while fat falls can leave the number on a set of scales roughly where it started. The 2007 trial was explicit about its target. Its primary end point was the percent change from baseline in visceral adipose tissue as shown on computed tomography, read in patients by scan rather than by weighing them. Read that carefully, because the design says something. A compound is tracked by scan when the two tissues it moves run in opposite directions, and a scan does not predict what a set of scales will show.

Question 8

Will tesamorelin build muscle?

Accepted Answer

Lean body mass has been measured in these trials, and strength and muscle size have not been measured in the way the question implies. A 2014 trial enrolled 39 obese men and women with reduced GH secretion and ran for a year. After 12 months, tesamorelin treatment led to a significantly greater increase in IGF-I than did placebo treatment in those adults. IGF-1 is a blood marker that rises when growth hormone output rises, so it marks that the compound did something rather than measuring anything about a muscle. One registered study did set out after a muscle outcome, and it stopped. The public registry holds a phase 2 entry on Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting, whose recorded status is terminated, with three participants enrolled. A 2026 primer covers the ground a lifter cares about and finds it empty, recording that tesamorelin has no supporting orthopaedic evidence at all.

Question 9

What did the liver trials find?

Accepted Answer

Liver fat is the only outcome besides abdominal fat with a full randomised trial behind it, and that result was positive and narrow. Non-alcoholic fatty liver disease, shortened to NAFLD, is fat building up inside the liver of someone who drinks little. A 2019 trial in Lancet HIV enrolled 61 patients, of whom 30 received tesamorelin and 30 received placebo. After 12 months, 35% of individuals receiving tesamorelin and 4% receiving placebo had a HFF of less than 5%, where HFF is the share of the liver made up of fat. The authors declined to overstate it, writing that tesamorelin might be beneficial in people with HIV and NAFLD, and that further studies are needed to determine the long-term effects of tesamorelin on liver histology. That is a genuine randomised result in 61 patients, every one of them living with HIV.

Question 10

How does tesamorelin make you feel?

Accepted Answer

Published trials did not ask that question directly, and the three nearest answers point in different directions. They did measure how patients felt about their appearance. The 2010 trial reports that tesamorelin improves body image distress in HIV-infected patients with central fat accumulation. That is a questionnaire score, which is narrower than mood and much narrower than how a day actually feels. Thinking was tested once, with waist circumference measured alongside it. A 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard of care in people with HIV. The authors found that in those participants, while tesamorelin reduced waist circumference, the cognitive benefits did not significantly differ between groups. The most commonly reported sensation is local. In the liver trial, individuals in the tesamorelin group experienced more localised injection site complaints than those in the placebo group.

Question 11

How long can someone stay on tesamorelin?

Accepted Answer

The longest published course in these trials runs 52 weeks, and what happened at the end of that year is the part of the published record worth knowing. A 26-week extension phase followed the patients from the first large trial, and across both phases the change in VAT was sustained at -18% over 52 weeks of treatment. The prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase. Then the authors state the limit of their own finding: though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment. A 2011 review puts the same point the other way round, recording that discontinuation of therapy during this period resulted in the reaccumulation of VAT in those patients. The shape of that finding matters more than the percentage itself, because the fat came back once the injections stopped. That makes it an ongoing course rather than a correction that holds, and nothing published among the research behind this page follows anyone past a year.

Question 12

What else has tesamorelin been tested in?

Accepted Answer

Quite a lot of things, early on, and almost none of those lines were ever carried through to an approval. A 2006 drug evaluation lists what the developer was aiming at. The firm was then working on tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Of that long list, only the lipodystrophy line ever reached a regulator. Two registered studies are recent or still open. One phase 2 entry covers Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury, and its status there is recruiting. A 2026 protocol sets out a randomised trial of 100 sedentary older adults living with HIV who are frail or at risk for frailty. Read that list as a map of intentions rather than of results, because a compound entering a trial is only a hypothesis until it leaves one.

Question 13

Do doctors prescribe tesamorelin?

Accepted Answer

For the indication it carries, yes, and the published price explains a good deal of what happens around it. A 2016 reimbursement review sets out the economics without comment. The submitted price is $3,085 per box of 60 vials (30-day supply), and the annual cost of treatment is $37,534 per patient. The same review records the gate the label puts in front of a prescription, which is that treatment with tesamorelin should be limited to patients who failed to reduce excess VAT using diet and exercise. A 2012 review names the practical limits in the same breath as the benefit, listing high cost and lack of long-term safety and adherence data. Beside the approved injection sits compounded material, prepared by a pharmacy rather than released against an approved label. The two are easy to confuse, and the FDA enforcement record is where the difference shows.

Question 14

Is tesamorelin prohibited in sport?

Accepted Answer

It is, and the prohibition is written against the whole class rather than this one compound. A 2021 analytical paper opens with the position. The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Tesamorelin is one of the four analogues that paper set out to detect in urine. Detection lagged the ban for years. The authors note that although there is evidence of their use, based on admissions and intelligence, they do not appear to have been found in anti-doping samples by WADA accredited laboratories. Their own method closed part of that gap, reaching limits of detection of the target peptides were generally 1 ng/ml (WADA required performance limit) or less. That changes the position for anyone subject to testing. A rule nobody could enforce and a rule with a validated assay behind it are different rules, even with the same wording.

Question 15

What do the FDA recall records show?

Accepted Answer

Two Class II recalls of compounded tesamorelin sit on the enforcement record, and they document two different failures. The 2025 entry covers Tesamorelin for Injection, 15mg, 10 mL Multi-Dose Vial from a Florida compounding firm, withdrawn for lack of assurance of sterility. The 2018 entry covers a Kentucky firm's lyophilized powder for reconstitution, withdrawn because the vial indicates a 1 year expiration date instead of a 6 month expiration date. Neither entry is a finding about the molecule. One is about whether a vial could be relied on as sterile, the other about whether its printed date was right. What the pair establish is the distance between the approved record and a compounded vial. The approval was granted against one dossier and one manufacturing standard, and neither of those travels with material prepared somewhere else.

Question 16

What is documented about side effects?

Accepted Answer

The adverse events in these trials fall into two groups, and the reviews name both of them. Arthralgia means joint pain, and peripheral oedema means swelling in the hands, feet or ankles. A 2011 review records that most of these events were injection-site reactions or events known to be associated with growth hormone therapy (e.g. arthralgia, headache and peripheral oedema), with serious adverse events occurring in <4% of patients during 26 weeks of therapy. A 2026 systematic review found a second pattern across the pooled data, reporting growth hormone-related adverse effects and higher discontinuation rates. It adds that limited data on long-term safety warrant caution. A 2012 monograph reads the liver on its own. It records that tesamorelin has not been linked to serum aminotransferase elevations during therapy, nor to clinically apparent acute liver injury in patients. Those enzymes are what a routine liver panel reads.

Question 17

How is tesamorelin thought to work?

Accepted Answer

The route runs through the pituitary gland, and every measurement sits a step or two below it. Tesamorelin stimulates the synthesis and release of endogenous growth hormone, which is the hormone a body makes for itself. Growth hormone then raises IGF-1 in the blood, and IGF-1 is the marker these trials follow to show that the signal got where it was meant to go. A 2020 study went deeper, into liver tissue taken during a randomised trial. In those participants tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation, which is the way a cell makes most of its energy. A 2014 trial tied that to something you can measure in a person. In those adults, increases in IGF-I were significantly associated with improvements in PCr recovery parameters. That is a scan test of how fast a muscle refuels once hard exercise has stopped.

Tesamorelin